Cargando…

Pharmacokinetic profile of a 24-hour controlled-release OROS(® )formulation of hydromorphone in the presence and absence of food

BACKGROUND: The objective of this study was to compare the pharmacokinetic profile of a novel, once-daily, controlled-release formulation of hydromorphone (OROS(® )hydromorphone) under fasting conditions with that immediately after a high-fat breakfast in healthy volunteers. The effect of the opioid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sathyan, Gayatri, Xu, Emily, Thipphawong, John, Gupta, Suneel K
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1810515/ https://www.ncbi.nlm.nih.gov/pubmed/17270055 http://dx.doi.org/10.1186/1472-6904-7-2

Ejemplares similares

Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone
por: Sathyan, Gayatri, et al.
Publicado: (2007)

A randomized, double-blind comparison of OROS(® )hydromorphone and controlled-release morphine for the control of chronic cancer pain
por: Hanna, Magdi, et al.
Publicado: (2008)

A new extended release formulation (OROS(®)) of hydromorphone in the management of pain
por: Weinstein, Sharon M
Publicado: (2009)

Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain
por: Vandenbossche, Joris, et al.
Publicado: (2012)

Once-daily OROS® hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study
por: Wallace, M, et al.
Publicado: (2007)

An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(® )hydromorphone in patients with chronic cancer pain
por: Hanna, Magdi, et al.
Publicado: (2009)

Complementary pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during single-dose and steady-state dosing
por: Devarakonda, Krishna, et al.
Publicado: (2013)

Pharmacokinetics of Rytary(®), An Extended-Release Capsule Formulation of Carbidopa–Levodopa
por: Mittur, Aravind, et al.
Publicado: (2017)

Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone extended release in opioid-tolerant patients with chronic low back pain
por: Hale, Martin E, et al.
Publicado: (2013)

Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study
por: Park, Cheol Kyu, et al.
Publicado: (2016)

Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label Study
por: Shin, Seong Hoon, et al.
Publicado: (2014)

Single dose epidural hydromorphone in labour pain: maternal pharmacokinetics and neonatal exposure
por: Puhto, Terhi, et al.
Publicado: (2020)

Controlled-release hydromorphone and risk of infection in adults: a systematic review
por: Tricco, Andrea C., et al.
Publicado: (2023)

A prospective multicentre study to evaluate the efficacy and tolerability of osmotic release oral system (OROS(®)) hydromorphone in opioid-naive cancer patients: Results of the Korean South West Oncology Group study
por: Song, Eun-Kee, et al.
Publicado: (2015)

Steady-State Pharmacokinetics of Intravenous Hydromorphone in Japanese Patients With Renal Impairment and Cancer Pain
por: Nakatani, Toshihiko, et al.
Publicado: (2023)

Selection of 12‐Hour Sustained‐Release Acetaminophen (Paracetamol) Formulation Through Comparison of Pharmacokinetic Profiles of 4 Sustained‐Release Prototype Formulations and Standard Acetaminophen Formulation: An Open‐Label, Randomized, Proof‐of‐Principle Pharmacokinetic Study
por: Yue, Yong, et al.
Publicado: (2017)

Effect of an Experimental Formulation Containing Chlorhexidine on Pathogenic Biofilms and Drug Release Behavior in the Presence or Absence of Bacteria
por: Ré, Ana Carolina S., et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of Immediate- and Modified-Release Mycophenolic Acid Preparations in Healthy Beagle Dogs
por: Klotsman, Michael, et al.
Publicado: (2021)

Acute suicidal ideations responsive to hydromorphone
por: Rotchford, James Kimber
Publicado: (2019)

Unintentional administration of intra‐articular hydromorphone
por: Doyle, Stephen, et al.
Publicado: (2021)

Analgosedation: The Use of Fentanyl Compared to Hydromorphone
por: Choi, Hahnl, et al.
Publicado: (2021)

Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet(®)), sustained‐release carbidopa‐levodopa (Sinemet(®) CR), and carbidopa‐levodopa‐entacapone (Stalevo(®))
por: Hsu, Ann, et al.
Publicado: (2015)

Formulation and Evaluation of Loperamide HCl Oro Dispersible Tablets
por: Alejandro, Blasco, et al.
Publicado: (2020)

Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers
por: Farr, Stephen J, et al.
Publicado: (2015)

Extended‐Release Once‐Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate‐Release Tofacitinib and Impact of Food
por: Lamba, Manisha, et al.
Publicado: (2016)

Phase I and Pharmacokinetic Study of Paclitaxel by 24‐Hour Intravenous Infusion
por: Tamura, Tomohide, et al.
Publicado: (1994)

Mycobacteremia from Crushed Hydromorphone Tablet Injection
por: Banno, Joseph M, et al.
Publicado: (2017)

Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder
por: Biederman, Joseph, et al.
Publicado: (2007)

Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers
por: van Rongen, A, et al.
Publicado: (2015)

Limitations of 24-hour Recall Method: Micronutrient Intake and the Presence of the Metabolic Syndrome
por: Raina, Sunil Kumar
Publicado: (2013)

Tendrás oro y oro /
por: Sender, Rafael
Publicado: (1985)

The protective effect of hydromorphone to ischemia in rat glial cells
por: Kim, Young Sung, et al.
Publicado: (2016)

Two orthorhombic polymorphs of hydromorphone
por: Mazurek, Jaroslaw, et al.
Publicado: (2016)

Hydromorphone/lorazepam/morphine overdose: Coma: case report
Publicado: (2019)

Formulation and evaluation of microsphere based oro dispersible tablets of itopride hcl
por: Shah, Sanjay, et al.
Publicado: (2012)

Agreement between 24-hour urine and 24-hour food recall in measuring salt intake in primary school children in Australia
por: Santos, Joseph Alvin, et al.
Publicado: (2022)

Fasting for 24 Hours Heightens Reward from Food and Food-Related Cues
por: Cameron, Jameason D., et al.
Publicado: (2014)

A randomized, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain reLief)
por: Inoue, Satoshi, et al.
Publicado: (2017)

Effects of food on pharmacokinetics of immediate release oral formulations of aspirin, dipyrone, paracetamol and NSAIDs – a systematic review
por: Moore, Robert Andrew, et al.
Publicado: (2015)

Evaluation of a 12‐Hour Sustained‐Release Acetaminophen (Paracetamol) Formulation: A Randomized, 3‐Way Crossover Pharmacokinetic and Safety Study in Healthy Volunteers
por: Yue, Yong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_j2l2sh2qb63l134nut8u724jdg